Fig. 7: Potential targets for three molecular subtypes of ATC/PDTC. | Nature Communications

Fig. 7: Potential targets for three molecular subtypes of ATC/PDTC.

From: Integrative proteogenomic characterization reveals therapeutic targets in poorly differentiated and anaplastic thyroid cancers

Fig. 7

A Proposal of potential targets depending on proteome-based ATC/PDTC subtyping. B, C Immunohistochemistry staining of BCL2 in three proteomic subtypes (n = 4 samples in each group). Data are presented as mean ± SD, and statistical analysis was performed via one-way ANOVA, two-sided. D, E Immunofluorescence staining of C5AR1 and myeloid marker CD11b in three proteomic subtypes (n = 3 samples in each group). Data are presented as mean ± SD, and statistical analysis was performed via one-way ANOVA, two-sided. F, G The tumor growth curve and tumor size in an immunocompetent model of murine ATC after treating with avacopan, and/or anti-PD-1 as single agent and combination therapy (n = 6). Results show the mean of biological replicates. Error bars indicate SEM. H Immunofluorescence staining showing representative micrographs of MPO and cit-H3 in mATC-derived tumors after avacopan treatment. Experiment was repeated independently using 3 samples for each group with similar results. Source data are provided as a Source Data file.

Back to article page